Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker for predicting curative effect of harmful ventricular remodeling and immunotherapy of myocardial infarction patient and application of marker

A ventricular remodeling and immunotherapy technology, applied in biological testing, material testing, etc., can solve problems such as unpredictable risk of harmful ventricular remodeling and difficulty reflecting the level of cardiac inflammation in patients

Pending Publication Date: 2022-08-05
XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] At present, the common serum markers that can predict the level of cardiac inflammation in patients and whether patients can benefit from immunotherapy are mainly CRP. Patients with high levels were treated with immunotherapy, but the risk of heart failure hospitalization and heart failure death in the drug group was not significantly different from that in the untreated group
This suggests that currently available serum inflammatory markers do not reflect the level of cardiac inflammation in patients and therefore cannot predict the risk of harmful ventricular remodeling or distinguish patients who may benefit from immunotherapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for predicting curative effect of harmful ventricular remodeling and immunotherapy of myocardial infarction patient and application of marker
  • Marker for predicting curative effect of harmful ventricular remodeling and immunotherapy of myocardial infarction patient and application of marker
  • Marker for predicting curative effect of harmful ventricular remodeling and immunotherapy of myocardial infarction patient and application of marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 110

[0057] Example 1 10X genomics single-cell RNA sequencing

[0058] 1. Materials

[0059] 1.1 Clinical samples

[0060] Heart failure heart samples were obtained from patients with chronic heart failure (n=5) who received heart transplantation.

[0061] Inclusion criteria: Patients with heart failure with echocardiographic evidence of segmental left ventricular dyskinesia, ventricular aneurysm, or systolic dysfunction. Exclusion criteria: valvular heart disease; heart failure due to complex congenital heart disease; active infection; autoimmune disease; Vaccines; patients over 80 years old, pregnant women and children.

[0062] 1.2 Main instruments and equipment

[0063] 1) Surgical Instruments, Shanghai Surgical Instrument Factory, China

[0064] 2) Magnetic bead sorting rack, Miltenyi Biotec, Germany

[0065] 3) High-speed centrifuge, Eppendorf, Germany

[0066] 4) MS separation column, Miltenyi Biotec, Germany

[0067] 5) Micropipette, Eppendorf, Germany

[0068] 6) ...

Embodiment 2

[0124] Example 2 Verification of the specific high expression of inflammatory factors in macrophages of failing heart

[0125] 1. Materials

[0126] 1.1 Clinical samples

[0127] Heart failure heart samples were obtained from chronic heart failure patients undergoing heart transplantation (n=5) and healthy heart samples were obtained from multiple organ donors (n=5).

[0128] Inclusion criteria: Heart failure patients with segmental left ventricular dyskinesia, ventricular aneurysm, or systolic dysfunction on echocardiography. Exclusion criteria: valvular heart disease; heart failure due to complex congenital heart disease; active infection; autoimmune disease; Vaccines; patients over 80 years old, pregnant women and children.

[0129] Inclusion criteria for the control group: individuals with normal ventricular systolic function and no structural cardiac disease on echocardiography. Exclusion criteria: valvular heart disease; heart failure of various causes; history of ac...

Embodiment 3

[0166] Example 3 Detection of combined indexes of serum inflammatory factors

[0167] 1. Materials

[0168] 1.1 Clinical samples

[0169] Peripheral blood samples from patients with heart failure were obtained from hospitalized patients with chronic heart failure (n=23); peripheral blood in the control group was obtained from hospitalized patients with non-chronic heart failure.

[0170] Inclusion criteria for the chronic heart failure study: patients with heart failure with echocardiographic evidence of segmental left ventricular dyskinesia, ventricular aneurysm, or systolic dysfunction. Exclusion criteria: valvular heart disease; heart failure due to complex congenital heart disease; active infection; autoimmune disease; Vaccines; patients over 80 years old, pregnant women and children.

[0171] Inclusion criteria for the control group: individuals with normal ventricular systolic function and no structural cardiac disease on echocardiography. Exclusion criteria: valvula...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a marker for predicting the curative effect of harmful ventricular remodeling and immunotherapy of myocardial infarction patients and application of the marker. The marker comprises granular protein, galectin 3, a complement factor D, a cysteine protease inhibitor 3 and C1q, the five markers are combined to be used as serum indexes for predicting harmful ventricular remodeling and immunotherapy curative effects of myocardial infarction patients, so that the requirements on specificity, accuracy, precision (including repeatability, day difference and personnel operation error) and the like in a verification process can be met; the method has important significance in predicting harmful ventricular remodeling and immunotherapy effects of myocardial infarction patients.

Description

technical field [0001] The present application relates to the field of in vitro diagnostic technology, in particular to markers for predicting adverse ventricular remodeling and immunotherapy efficacy in patients with myocardial infarction and their applications, and for determining the level of markers for predicting adverse ventricular remodeling and immunotherapy efficacy in patients with myocardial infarction or Amounts thereof, kits, chips and devices for predicting adverse ventricular remodeling and immunotherapy efficacy in patients with myocardial infarction. Background technique [0002] Chronic heart failure is an increasingly serious public health problem, and its morbidity is on the rise, causing a huge burden on patients and society. Heart failure is a clinical syndrome with a variety of symptoms and signs. It is a pathophysiological state in which the abnormal heart structure and function caused by a variety of causes lead to ventricular filling disorder, and t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2333/81G01N2800/324
Inventor 程翔唐婷婷张思
Owner XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com